Yahoo Web Search

Search results

1. ADMA Biologics, Inc.

   NasdaqGM: ADMA

   16.74

   Add to watchlist

   Sign in to add to watchlist

   Sign In

   -0.13 (-0.77%)

   At close:4:00 PM EDTThu. Sep 5, 2024

   16.74 0.00 (0.00%)

   After hrs:7:47 PM EDTThu. Sep 5, 2024

   Nasdaq Real Time Price (USD) · Market closed

   Full chart

   • 1D
   • 5D
   • 1M
   • 6M
   • YTD
   • 1Y
   • MAX

   • Open	16.79
     High	16.79
     Low	16.32

   • Mkt Cap	3.93B
     P/E (TTM)	119.57
     Div & Yield	N/A & N/A

   • Prev. Close	16.87
     52 Wk. Low	3.06
     52 Wk. High	18.48

   More about ADMA

   Related stocks

   • SONN
     Sonnet BioTherapeutics Holdings, Inc.
     SONN
     0.8550
     -5.00%
   • ABUS
     Arbutus Biopharma Corporation
     ABUS
     4.5100
     +10.27%
   • ALDX
     Aldeyra Therapeutics, Inc.
     ALDX
     6.32
     0.00%
   • ARDX
     Ardelyx, Inc.
     ARDX
     5.77
     +1.76%
   • XERS
     Xeris Biopharma Holdings, Inc.
     XERS
     2.5300
     -4.17%

   More on Yahoo Finance

2. ir.admabiologics.comInvestor Relations :: ADMA Biologics, Inc.

   ir.admabiologics.com

   • Cached

   Aug 14, 2024 · ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing, and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection.

   • Press Releases

     ADMA Biologics Announces Fourth Quarter and Full Year 2023...

   • Email Alerts

     To opt-in for investor email alerts, please select at least...

   • Financial Results

     Financial Results - Investor Relations :: ADMA Biologics,...

   • Balance Sheet

     Balance Sheet - Investor Relations :: ADMA Biologics, Inc.

   • Income Statement

     Income Statement - Investor Relations :: ADMA Biologics,...

   • Cash Flow

     Cash Flow - Investor Relations :: ADMA Biologics, Inc.

   • Annual Reports

     FISCAL YEAR ENDED DEC 31, 2022. Earnings Release 116.1 KB....

   • SEC Filings

     0001140361-24-038772.xls. Aug 26, 2024. Filed by "insiders"...

   • Stock Data & Quote

     Recent Price $17.35: Recent Price 8/27/24: 52 Week High...

   • ADMA Biologics 2Q 2024 Earnings Call

     ADMA Biologics 2Q 2024 Earnings Call - Investor Relations ::...

3. www.nasdaq.com › market-activity › stocksADMA Biologics Inc Common Stock - Nasdaq

   www.nasdaq.com › market-activity › stocks

   • Cached

   6 days ago · Discover real-time ADMA Biologics Inc Common Stock (ADMA) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.

4. stockanalysis.com › stocks › admaADMA Biologics, Inc. (ADMA) - Stock Analysis

   stockanalysis.com › stocks › adma

   • Cached

   2 days ago · ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

   • Market Cap: 4.08B
   • Revenue (ttm): 330.24M

   • Net Income (ttm): 34.79M
   • Shares Out: 233.08M

5. stockanalysis.com › stocks › admaADMA Biologics, Inc. (ADMA) Company Profile & Overview ...

   stockanalysis.com › stocks › adma

   • Cached

   Aug 30, 2024 · ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

6. finance.yahoo.com › news › adma-biologics-inc-admaADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still ...

   finance.yahoo.com › news › adma-biologics-inc-adma

   • Cached

   Aug 13, 2024 · Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

7. finance.yahoo.com › news › adma-shares-gain-bigADMA Shares Gain on Big Sales, Earnings Wins - Yahoo Finance

   finance.yahoo.com › news › adma-shares-gain-big

   • Cached

   Aug 30, 2024 · ADMA grew revenue by 78% on a year-over-year basis (to $107.2 million) and posted per-share earnings of $0.32. Profits jumped to $57.5 million, good for a gross margin of 53.6% versus 27.8% the ...

8. People also ask

   Who is ADMA biologics?

   • ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised...

   ADMA Biologics Inc Common Stock (ADMA) - Nasdaq

   www.nasdaq.com/market-activity/stocks/adma

   See all results for this question

   Who owns ADMA Biologics Inc stock?

   • Approximately 1. 50% of ADMA Biologics Inc. ’s shares are owned by company insiders. Institutional investors hold 67. 30% of the company’s shares. The data on short interest indicates that stock shorts accounted for 12. 79 million shares as on Jan 30, 2023, resulting in a short ratio of 4. 91.

   Things To Consider Before Buying ADMA Biologics Inc. (NASDAQ: ADMA)

   stocksregister.com/2023/03/25/things-to-consider-before-buying-adma-biologics-inc-nasdaq-adma/

   See all results for this question

   How will ADMA biologics perform in fiscal year?

   • For the current fiscal year, Adma Biologics is expected to post earnings of $0.41 per share on $410.3 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $0.59 per share on $466.3 million in revenues. This represents a year-over-year change of 44.71% and 13.65%, respectively.

   ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

   finance.yahoo.com/news/adma-biologics-inc-adma-hits-131506858.html

   See all results for this question

   How did ADMA biologics perform in 2023?

   • In 2023, ADMA Biologics's revenue was $258.22 million, an increase of 67.59% compared to the previous year's $154.08 million. Losses were -$28.24 million, -57.15% less than in 2022. Financial Statements Analyst Forecast According to 4 analysts, the average rating for ADMA stock is "Strong Buy."

   ADMA Biologics, Inc. (ADMA) Stock Price, Quote & News - Stock Analysis

   stockanalysis.com/stocks/adma/

   See all results for this question

9. www.marketscreener.com › quote › stockADMA Biologics, Inc. Stock - MarketScreener.com

   www.marketscreener.com › quote › stock

   • Cached

   6 days ago · ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.